» Articles » PMID: 35207611

An Immunological Perspective of Circulating Tumor Cells As Diagnostic Biomarkers and Therapeutic Targets

Overview
Journal Life (Basel)
Specialty Biology
Date 2022 Feb 25
PMID 35207611
Authors
Affiliations
Soon will be listed here.
Abstract

Immune modulation is a hallmark of cancer. Cancer-immune interaction shapes the course of disease progression at every step of tumorigenesis, including metastasis, of which circulating tumor cells (CTCs) are regarded as an indicator. These CTCs are a heterogeneous population of tumor cells that have disseminated from the tumor into circulation. They have been increasingly studied in recent years due to their importance in diagnosis, prognosis, and monitoring of treatment response. Ample evidence demonstrates that CTCs interact with immune cells in circulation, where they must evade immune surveillance or modulate immune response. The interaction between CTCs and the immune system is emerging as a critical point by which CTCs facilitate metastatic progression. Understanding the complex crosstalk between the two may provide a basis for devising new diagnostic and treatment strategies. In this review, we will discuss the current understanding of CTCs and the complex immune-CTC interactions. We also present novel options in clinical interventions, targeting the immune-CTC interfaces, and provide some suggestions on future research directions.

Citing Articles

A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells.

Bahmaie N, Ozensoy Guler O, Simsek E J Liq Biopsy. 2025; 6:100169.

PMID: 40027303 PMC: 11863822. DOI: 10.1016/j.jlb.2024.100169.


Nanomaterial-based detection of circulating tumor cells and circulating cancer stem cells for cancer immunotherapy.

Yun Y, Kim S, Lee S, Cho H, Choi J Nano Converg. 2024; 11(1):56.

PMID: 39671082 PMC: 11645384. DOI: 10.1186/s40580-024-00466-x.


Liquid biopsy: paving a new avenue for cancer research.

Kurma K, Eslami-S Z, Alix-Panabieres C, Cayrefourcq L Cell Adh Migr. 2024; 18(1):1-26.

PMID: 39219215 PMC: 11370957. DOI: 10.1080/19336918.2024.2395807.


Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors.

Magri V, De Renzi G, Marino L, De Meo M, Siringo M, Gelibter A Int J Mol Sci. 2024; 25(7).

PMID: 38612563 PMC: 11011814. DOI: 10.3390/ijms25073752.


Orthotopic model for the analysis of melanoma circulating tumor cells.

Pickova M, Kahounova Z, Radaszkiewicz T, Prochazkova J, Fedr R, Noskova M Sci Rep. 2024; 14(1):7827.

PMID: 38570556 PMC: 10991390. DOI: 10.1038/s41598-024-58236-y.


References
1.
Pimienta M, Edderkaoui M, Wang R, Pandol S . The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. Front Physiol. 2017; 8:381. PMC: 5454071. DOI: 10.3389/fphys.2017.00381. View

2.
Li J, King M . Adhesion receptors as therapeutic targets for circulating tumor cells. Front Oncol. 2012; 2:79. PMC: 3402858. DOI: 10.3389/fonc.2012.00079. View

3.
Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

4.
Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

5.
Paoli P, Giannoni E, Chiarugi P . Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013; 1833(12):3481-3498. DOI: 10.1016/j.bbamcr.2013.06.026. View